Be the first to like this
The pharmaceutical industry's steep patent cliff forces strategy and development executives to uncover opportunities for sustainable growth. One opportunity for growth lies in combination therapies with branded products to extend patent life. Fixed dose combination (FDC) products, which have been around for many years, can have clinical and commercial advantages. For the drug manufacturer, an FDC product can extend the therapeutic advantage and becomes part of lifecycle management. For the patient, FDC products can address unmet medical needs and reduce pill burdens.
Best Practices ®, LLC’s timely study identifies successful strategies and innovative practices for developing and bringing FDC products to market. Through executive insights and advice, the study also addresses the pitfalls and obstacles to avoid in this work.